companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and vital medicines, visit
www.amgen.com.
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)
Amgen Inc.Condensed Consolidated Statements of Income andReconciliation of GAAP Earnings to "Adjusted" Earnings(In millions, except per share data)(Unaudited)Three Months EndedThree Months EndedMarch 31, 2011March 31, 2010GAAPAdjustments
"Adjusted"GAAPAdjustments
"Adjusted"Revenues:Product sales$ 3,618$
-$
3,618$ 3,528$
-$
3,528Other revenues88-8864-64Total revenues3,706-3,7063,592-3,592Operating expenses:Cost of sales (excludes amortization of certainacquired intangible assets presented below)564(3)
(a)540508(4)
(a)504(10)
(b)(11)
(c)Research and development736(9)
(a)703646(12)
(a)617(17)
(d)(17)
(d)(7)
(e)Selling, general and administrative1,023(10)
(a)1,011884(11)
(a)873(2)
(f)Amortization of certain acquired intangible assets74(74)
(g)-74(74)
(g)-Other16(16)
(h)-(1)1
(i)-Total operating expenses2,413(159)2,2542,111(117)1,994Operating income1,2931591,4521,4811171,598Interest expense, net135(44)
(j)91145(65)
(j)80Interest and other income, net148-14884-84Income before income taxes1,3062031,5091,4201821,602Provision for income ta
'/>"/>
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related medicine technology :1.
Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.212.
Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year3.
Cepheid Reports 2011 First Quarter Results4.
ViroPharma to Release 2011 First Quarter Financial Results On April 28, 20115.
Caliper Life Sciences First Quarter Results Conference Call Notice6.
Siemens Applauds First Health System Customers to Successfully Attest to Meaningful Use7.
Cardiogenesis Corporation to Report 2011 First Quarter Results on May 4th8.
PDL BioPharma to Announce First Quarter 2011 Financial Results on April 27, 20119.
WuXi PharmaTech Schedules First-Quarter 2011 Earnings Release10.
Masimo to Report First Quarter 2011 Financial Results After Market Close on May 3, 201111.
MiMedx Group, Inc. Announces Release Date for First Quarter Results